Urinary N-Acetyl-Beta-D-Glucosaminidase levels predict immunoglobulin a nephropathy remission status

BMC Nephrology

Table 4 Multivariable logistic analyses of urinary NAG for predicting risk of IgAN progression in subgroups of eGFR

	Cut Points	Remission failure %	Unadjusted OR (95% Cl); P	Adjusted OR (95% Cl)
	Cut Points	Remission failure %	Unadjusted OR (95% Cl); P	Model 1^a, P	Model 2^b, P	Model 3^c, P
Subgroup with eGFR ≥ 60 ml/min/1.73 m² (n = 142)
T1 + T2 urinary NAG (n = 101)	≤ 22.32	6.9	1.0 (referent)	1.0 (referent)	1.0 (referent)	1.0 (referent)
T3 urinary NAG (n = 41)	> 22.32	31.7	6.23 (2.27–17.14); <0.001	5.62 (1.97-16.00); 0.001	5.05 (1.66–15.37); 0.004	4.01 (1.24–12.93); 0.020
Subgroup with eGFR < 60 ml/min/1.73 m² (n = 71)
T1 + T2 urinary NAG (n = 41)	≤ 22.32	14.6	1.0 (referent)	1.0 (referent)	1.0 (referent)	1.0 (referent)
T3 urinary NAG (n = 30)	> 22.32	56.7	7.63 (2.47–23.56); <0.001	7.85 (2.38–25.87); 0.001	3.16 (0.44–22.43); 0.250	3.38 (0.46–25.01); 0.233

Abbreviations: Cl, confidence interval; Cr, creatinine; OR, Odds ratio; BMI, body mass index; eGFR, estimated glomerular filtration rate; MAP, mean arterial blood pressure; MEST-C, histologic score based on mesangial hypercellularity, the presence of endocapillary proliferation, segmental glomerulosclerosis/adhesion, and severity of tubular atrophy/interstitial fibrosis, and crescents formation; T, tertile
^aModel 1 adjusted for age, sex, MAP, BMI
^bModel 2 adjusted for covariates in model 1 plus 24-hour proteinuria, eGFR and Oxford MEST-C score
^cModel 3 adjusted for covariates in model 1 and 2 plus use of renin-angiotensin system inhibition and immunosuppression during follow-up

ISSN: 1471-2369